However, our results may also demonstrate that IL-17A and IL-17F act in epistasis, and possibly argue that both pathways must be engaged for NAFLD pathogenesis–something that may occur in parallel and/or in multiple cell types. Here, IL17F is linked to metabolic dysfunction-associated steatotic liver disease.